Can-Fite BioPharma

CIK 0001536196 · CANF NYSE American

SIC
2834 · Pharmaceutical Preparations
Status
Public
FY End
Dec 31

About Can-Fite BioPharma

Can-Fite BioPharma Ltd is an SEC registrant, classified under SIC 2834 (Pharmaceutical Preparations). It files with the SEC under Central Index Key 0001536196, and its shares are listed as CANF on NYSE American. Its most recent filing on EDGAR is a 6-K, filed November 18, 2026. 12 institutional investment managers reported holding its shares on Form 13F for Q3 2026, against 9 in Q2 2026. Its officers, directors and 10% owners have filed 2 Form 4 reports since 2026. 1 registered fund reports holding its shares on Form N-PORT.

Across SEC filings

Institutional holders · 13F

Q3 2026
12 managers reported a position for Q3 2026 +3 vs Q2 2026
Largest Q3 2026 Form 13F holders of Can-Fite BioPharma by reported value
Largest holders Reported value
SABBY MANAGEMENT LLC $187.5K
CITADEL ADVISORS LLC $59.2K
RHUMBLINE ADVISERS $42.8K
JANE STREET GROUP LLC $29.3K
GAMMA Investing LLC $14.8K

Securities

Securities issued by this company
CUSIP Security Type
13471N409 CANF CAN FITE BIOPHARMA LTD-ADR Adr

Insider trades · Form 4

No open-market purchases or sales by Can-Fite BioPharma insiders in the last 12 months.

Latest filings

Funds & ETFs · N-PORT

1 fund
Largest fund holders reported on Form N-PORT
Fund Value % of fund
Blackstone Alternative Multi-Strategy Fund $149 < 0.01%

1 fund reported holding $149 in total on their latest public Form N-PORT reports, the most recent dated June 2026. Security record

Latest SEC filings

All filings →
Latest SEC filings by Can-Fite BioPharma
Form Description Filed
6-K REPORT OF FOREIGN PRIVATE ISSUER 2026-11-18
6-K REPORT OF FOREIGN PRIVATE ISSUER 2026-11-12
6-K REPORT OF FOREIGN PRIVATE ISSUER 2026-11-09
6-K REPORT OF FOREIGN PRIVATE ISSUER 2026-11-02
6-K REPORT OF FOREIGN PRIVATE ISSUER 2026-10-26
EFFECT EFFECT 2026-10-09
EFFECT EFFECT 2026-10-09
424B3 PROSPECTUS 2026-10-09
F-3 REGISTRATION STATEMENT 2026-09-25
F-3/A AMENDMENT NO. 1 TO FORM F-3 2026-09-25
Loading ownership data...
Loading insider trading data...
Loading financials...

Quality is a Plus feature

See why the score is what it is — the score history and the full test-by-test breakdown behind the composite.

Valuation is a Premium feature

What this company is worth versus its price — fair value at today's bond rate, margin of safety, and the Graham Number against the institutional consensus price.

Loading SEC filings...